Breaking News Instant updates and real-time market news.

VRTX

Vertex

$213.24

3.23 (1.54%)

, CRSP

Crispr Therapeutics

$72.97

14.45 (24.69%)

11:03
11/19/19
11/19
11:03
11/19/19
11:03

Cantor boosts Vertex target to $229 after 'highly encouraging' data

Cantor Fitzgerald analyst Alethia Young raised her price target for Vertex Pharmaceuticals (VRTX) to $229 from $217 after the company and partner Crispr Therapeutics (CRSP) announced the first CTX001 early clinical data in two patients. The first patient with beta thalassemia had nine months of follow up and the second sickle cell patient had four months of follow up, Young tells investors in a research note. The analyst finds the data "highly encouraging" and thinks this could be an "exciting pipeline program of focus for Vertex by this time next year." She increased her probability of success for CTX001 to 20% from 10% and reiterates an Overweight rating on shares of Vertex.

VRTX

Vertex

$213.24

3.23 (1.54%)

CRSP

Crispr Therapeutics

$72.97

14.45 (24.69%)

  • 19

    Nov

  • 07

    Dec

  • 19

    Mar

VRTX Vertex
$213.24

3.23 (1.54%)

11/12/19
RHCO
11/12/19
INITIATION
Target $235
RHCO
Buy
Vertex initiated with a Buy at SunTrust
SunTrust analyst Robyn Karnauskas initiated coverage of Vertex with a Buy rating and $235 price target. The analyst is positive on the company's high growth rate, with a 5-year earnings growth of 17.7% vs. the U.S. Pharma mean of 6.2%. Karnauskas contends that in the current challenging market, predictable growth names like Vertex may perform better.
11/18/19
PIPR
11/18/19
NO CHANGE
Target $247
PIPR
Overweight
Piper says Vertex partnership with Molecular Templates complements Crispr pact
Piper Jaffray analyst Edward Tenthoff said Vertex's (VRTX) newly announced partnership with Molecular Templates to use the latter's Engineered Toxin Bodies platform to discover novel targeted conditioning regimens to improve hematopoietic stem cell transplants is "uniquely complementary" to Vertex's existing partnership with Crispr Therapeutics (CRSP) to treat beta thalassemia and sickle cell disease patients. The company believes this technology could essentially replace intensive chemotherapy pre-conditioning regimens, allowing it to present a safer, more effective option for patients, Tenthoff said. He maintains an Overweight rating and $247 price target on Vertex shares.
11/19/19
GUGG
11/19/19
UPGRADE
Target $252
GUGG
Buy
Vertex upgraded to Buy from Neutral at Guggenheim
Guggenheim upgraded Vertex to Buy from Neutral with a $252 price target.
11/19/19
PIPR
11/19/19
NO CHANGE
Target $107
PIPR
Overweight
Piper 'impressed' by Crispr Therapeutics data, boosts price target to $107
Piper Jaffray analyst Edward Tenthoff raised his price target for Crispr Therapeutics (CRSP) to $107 from $100 after the company and partner Vertex Pharmaceuticals (VRTX) reported first-ever CTX001 data on one beta thalassemia and one sickle cell disease patient. The stock in premarket trading is up 7%, or $3.87, to $62.40. Both patients safely engrafted with five serious adverse events deemed CTX001 unrelated, Tenthoff tells investors in a research note. The beta thalassemia patient previously averaged 16.5 transfusions per year and was transfusion independent for nine months, while the sickle cell patient has been vaso-occlusive crises free for four months, the analyst points out. Tenthoff is "impressed by these early results showing potential curative effect and look for more patients and longer follow-up next year." He reiterates an Overweight rating on Crispr Therapeutics.
CRSP Crispr Therapeutics
$72.97

14.45 (24.69%)

11/12/19
OPCO
11/12/19
UPGRADE
Target $65
OPCO
Outperform
Crispr Therapeutics upgraded to Outperform from Perform at Oppenheimer
Oppenheimer analyst Silvan Tuerkcan upgraded Crispr Therapeutics to Outperform from Perform with a $65 price target.
11/12/19
OPCO
11/12/19
UPGRADE
Target $65
OPCO
Outperform
Crispr Therapeutics upgraded to Outperform from Perform at Oppenheimer
Oppenheimer analyst Silvan Tuerkcan upgraded Crispr Therapeutics to Outperform from Perform with a $65 price target. In a research note to investors, Tuerkcan says Crispr has made significant progress in moving CRISPR/Cas9-based editing from the bench into the clinic, and expects to see first proof-of-concept data from several assets over the next 12-18 months. The analyst views Crispr as well positioned and says he views Crispr's development strategy as well thought out, as its clinical pipeline is most focused on improving "established" approaches while more complex projects are pursued in a second wave.

TODAY'S FREE FLY STORIES

MMM

3M

$163.96

-3.145 (-1.88%)

12:32
12/05/19
12/05
12:32
12/05/19
12:32
Hot Stocks
Breaking Hot Stocks news story on 3M »

3M shares down 2% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

MMM

3M

$163.96

-3.145 (-1.88%)

12:31
12/05/19
12/05
12:31
12/05/19
12:31
Hot Stocks
3M CFO says Q4 'looks a lot like Q3,' some 'hopefulness' around end markets »

CFO Michael Roman says he…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

AXTA

Axalta Coating

$30.13

0.54 (1.82%)

12:25
12/05/19
12/05
12:25
12/05/19
12:25
Options
Axalta Coating call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$35.30

0.25 (0.71%)

, TSLA

Tesla

$330.39

-2.78 (-0.83%)

12:25
12/05/19
12/05
12:25
12/05/19
12:25
Periodicals
GM CEO sees big opportunity in all-electric pickup trucks, CNBC reports »

General Motors (GM) CEO…

GM

General Motors

$35.30

0.25 (0.71%)

TSLA

Tesla

$330.39

-2.78 (-0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Jan

HOV

Hovnanian

$24.73

3.39 (15.89%)

12:23
12/05/19
12/05
12:23
12/05/19
12:23
Earnings
Hovnanian surges 15% after Q4 report, revenue and deliveries climb »

Shares of home-builder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
12/05/19
12/05
12:17
12/05/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
12/05/19
12/05
12:16
12/05/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LUV

Southwest

$55.72

-0.05 (-0.09%)

12:15
12/05/19
12/05
12:15
12/05/19
12:15
Options
Southwest put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 12

    Dec

  • 23

    Jan

SIGA

Siga Technologies

$4.39

-0.01 (-0.23%)

12:13
12/05/19
12/05
12:13
12/05/19
12:13
Hot Stocks
Siga announces CDND intent to purchase up to 15,325 courses of oral TPOXX »

SIGA Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OPRT

Oportun Financial

$20.06

0.04 (0.20%)

12:11
12/05/19
12/05
12:11
12/05/19
12:11
Conference/Events
Oportun Financial management to meet with Jefferies »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

GALT

Galectin Therapeutics

$2.98

-0.06 (-1.97%)

12:09
12/05/19
12/05
12:09
12/05/19
12:09
Hot Stocks
Galectin Therapeutics plans adaptively designed Phase 3 NASH-RX trial »

Galectin Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$348.04

-0.85 (-0.24%)

12:09
12/05/19
12/05
12:09
12/05/19
12:09
Periodicals
Boeing to SEC: Doesn't see 737 MAX cancellations impacting revenue, Reuters says »

In a letter to the SEC,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MASI

Masimo

$156.34

-1.11 (-0.70%)

12:05
12/05/19
12/05
12:05
12/05/19
12:05
Conference/Events
Masimo management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

ACHN

Achillion

$6.16

-0.025 (-0.40%)

12:05
12/05/19
12/05
12:05
12/05/19
12:05
Options
Achillion call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 19

    Dec

TVTY

Tivity Health

$22.60

-0.23 (-1.01%)

12:04
12/05/19
12/05
12:04
12/05/19
12:04
Conference/Events
Tivity Health management to meet with Piper Jaffray »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

MIC

Macquarie Infrastructure

$42.49

0.43 (1.02%)

12:04
12/05/19
12/05
12:04
12/05/19
12:04
Conference/Events
Macquarie Infrastructure management to meet with Suntrust »

Group Dinner with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

TCBK

TriCo Bancshares

$38.57

0.09 (0.23%)

12:03
12/05/19
12/05
12:03
12/05/19
12:03
Conference/Events
TriCo Bancshares management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 11

    Dec

  • 11

    Dec

FB

Facebook

$198.74

0.04 (0.02%)

, NKE

Nike

$94.84

1.12 (1.20%)

12:02
12/05/19
12/05
12:02
12/05/19
12:02
On The Fly
Fly Intel: Wall Street's top stories at midday »

After two volatile days…

FB

Facebook

$198.74

0.04 (0.02%)

NKE

Nike

$94.84

1.12 (1.20%)

AAPL

Apple

$263.99

2.21 (0.84%)

WORK

Slack Technologies

$22.30

0.61 (2.81%)

VRNT

Verint

$52.36

4.54 (9.49%)

AUPH

Aurinia Pharmaceuticals

$16.22

7.84 (93.56%)

SIG

Signet Jewelers

$18.21

1.56 (9.37%)

SPWH

Sportsman's Warehouse

$8.03

0.67 (9.10%)

SAGE

Sage Therapeutics

$63.20

-86.02 (-57.65%)

HOME

At Home Group

$5.61

-2.94 (-34.39%)

ESTC

Elastic

$65.45

-12.98 (-16.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 09

    Dec

  • 16

    Dec

  • 19

    Dec

PK

Park Hotels & Resorts

$23.53

-0.09 (-0.38%)

12:02
12/05/19
12/05
12:02
12/05/19
12:02
Conference/Events
Park Hotels & Resorts management to meet with Suntrust »

Hotel Property Tour with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

BRY

Berry Petroleum

$8.35

0.23 (2.83%)

12:02
12/05/19
12/05
12:02
12/05/19
12:02
Conference/Events
Berry Petroleum management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

BAH

Booz Allen

$72.59

0.26 (0.36%)

, AMZN

Amazon.com

$1,745.65

-15.55 (-0.88%)

12:01
12/05/19
12/05
12:01
12/05/19
12:01
Hot Stocks
Booz Allen says has capabilities to support AWS Outposts »

Booz Allen Hamilton (BAH)…

BAH

Booz Allen

$72.59

0.26 (0.36%)

AMZN

Amazon.com

$1,745.65

-15.55 (-0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOV

Hovnanian

$24.49

3.15 (14.76%)

12:00
12/05/19
12/05
12:00
12/05/19
12:00
Hot Stocks
Hovnanian rises 14.2% »

Hovnanian is up 14.2%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

AZZ

AZZ Inc.

$44.00

5.63 (14.67%)

12:00
12/05/19
12/05
12:00
12/05/19
12:00
Hot Stocks
AZZ Inc. rises 14.4% »

AZZ Inc. is up 14.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

EXPR

Express

$4.74

0.845 (21.72%)

12:00
12/05/19
12/05
12:00
12/05/19
12:00
Hot Stocks
Express rises 21.1% »

Express is up 21.1%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

CSIQ

Canadian Solar

$18.04

0.6 (3.44%)

, FSLR

First Solar

$53.47

-1.33 (-2.43%)

11:57
12/05/19
12/05
11:57
12/05/19
11:57
Periodicals
U.S. trade court grants injunction in solar tariff dispute, Bloomberg says »

The U.S. Court of…

CSIQ

Canadian Solar

$18.04

0.6 (3.44%)

FSLR

First Solar

$53.47

-1.33 (-2.43%)

JASO

JA Solar

$0.00

(0.00%)

SPWR

SunPower

$7.25

-0.12 (-1.63%)

TSL

Trina Solar

$0.00

(0.00%)

YGE

Yingli Green Energy

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.